PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 15613921-2 2004 Here we show that HPRG adsorbed to a glycosaminoglycan (GAG) surface also binds Plg with a Kd value of 0.7 micromol/l. Glycosaminoglycans 56-59 plasminogen Homo sapiens 80-83 15613921-2 2004 Here we show that HPRG adsorbed to a glycosaminoglycan (GAG) surface also binds Plg with a Kd value of 0.7 micromol/l. Glycosaminoglycans 37-54 plasminogen Homo sapiens 80-83 15613921-4 2004 Specifically, Plg complexed with HPRG on a GAG surface is more readily activated by tissue-type Plg activator than free Plg, with a 10-fold difference in apparent catalytic efficiency (kcat/Km). Glycosaminoglycans 43-46 plasminogen Homo sapiens 14-17 15613921-4 2004 Specifically, Plg complexed with HPRG on a GAG surface is more readily activated by tissue-type Plg activator than free Plg, with a 10-fold difference in apparent catalytic efficiency (kcat/Km). Glycosaminoglycans 43-46 plasminogen Homo sapiens 96-99 15613921-4 2004 Specifically, Plg complexed with HPRG on a GAG surface is more readily activated by tissue-type Plg activator than free Plg, with a 10-fold difference in apparent catalytic efficiency (kcat/Km). Glycosaminoglycans 43-46 plasminogen Homo sapiens 96-99 15613921-5 2004 HPRG also augments the increase in Plg activation caused by fibrinogen fragments either in solution or on GAG surfaces. Glycosaminoglycans 106-109 plasminogen Homo sapiens 35-38 11776053-11 2000 GAG significantly inhibited the polymerization of fibrin monomer and enhanced the activity of plasmin in a concentration dependent manner. Glycosaminoglycans 0-3 plasminogen Homo sapiens 94-101 15203110-5 2004 Heparin, heparan sulfate and dermatan sulfate, at various HARP to glycosaminoglycan ratios, partially protect HARP from plasmin degradation. Glycosaminoglycans 66-83 plasminogen Homo sapiens 120-127 11776053-17 2000 The acceleration of colt lysis by GAG depended on its ability to increase the activity of plasmin, to inhibit the polymerizing of fibrin monomer, and consequently, to alter the architecture of the fibrin net work. Glycosaminoglycans 34-37 plasminogen Homo sapiens 90-97 1376317-6 1992 Binding of Lys-plasminogen and active-site-blocked plasmin was at least 10-fold higher in affinity (KD = 85-100 nM) compared to Glu-plasminogen (KD approximately 1 microM) and could be inhibited by lysine analogs but not by glycosaminoglycans or PAI-1, indicating that heteropolar plasmin(ogen) binding of VN occurs to an adjacent segment upstream to the heparin and PAI-1-binding sites. Glycosaminoglycans 224-242 plasminogen Homo sapiens 15-22 7561447-5 1995 Sulfur 35-labeled glycosaminoglycans (35S-GAGs) of HUVECs were decreased 1 hour after the incubation of plasmin with HUVECs, and the thrombomodulin (TM) activity of HUVECs measured by protein C activation capacity was decreased 6 hours after the incubation. Glycosaminoglycans 18-36 plasminogen Homo sapiens 104-111 1376317-6 1992 Binding of Lys-plasminogen and active-site-blocked plasmin was at least 10-fold higher in affinity (KD = 85-100 nM) compared to Glu-plasminogen (KD approximately 1 microM) and could be inhibited by lysine analogs but not by glycosaminoglycans or PAI-1, indicating that heteropolar plasmin(ogen) binding of VN occurs to an adjacent segment upstream to the heparin and PAI-1-binding sites. Glycosaminoglycans 224-242 plasminogen Homo sapiens 51-58 25937317-3 2015 Proteins enriched in lysine and other positively charged residues (histidine and arginine) as well as glycosaminoglycans and gangliosides bind Plg. Glycosaminoglycans 102-120 plasminogen Homo sapiens 143-146 1720904-3 1991 Since the GAG binding region is rich in arginyl and lysyl residues, it is a potential target for enzymes such as plasmin. Glycosaminoglycans 10-13 plasminogen Homo sapiens 113-120 1720904-8 1991 Thus, the plasmin-mediated proteolysis of the GAG binding activity of VN could destroy the antifibrinolytic activity of VN during physiologic conditions and during thrombolytic therapy. Glycosaminoglycans 46-49 plasminogen Homo sapiens 10-17 27976897-0 2017 Potent, Selective, Allosteric Inhibition of Human Plasmin by Sulfated Non-Saccharide Glycosaminoglycan Mimetics. Glycosaminoglycans 85-102 plasminogen Homo sapiens 50-57 27976897-3 2017 We report on the synthesis, biological activity, and mechanism of action of a group of small molecules, called non-saccharide glycosaminoglycan mimetics (NSGMs), as direct allosteric plasmin inhibitors. Glycosaminoglycans 126-143 plasminogen Homo sapiens 183-190 27301418-3 2016 Here we show that plasmin cleaves surface-bound CCL21 to release the C-terminal peptide responsible for CCL21 binding to glycosaminoglycans on the extracellular matrix and cell surfaces, thereby generating the soluble form. Glycosaminoglycans 121-139 plasminogen Homo sapiens 18-25 27564657-3 2016 Thrombomodulin enhances thrombin-mediated TAFI activation and glycosaminoglycans enhance plasmin-mediated TAFI activation. Glycosaminoglycans 62-80 plasminogen Homo sapiens 89-96 6448845-4 1980 Subsequently, we demonstrated that labeled heparin could be utilized in conjunction with fluorescence polarization spectroscopy to monitor the binding of mucopolysaccharide to thrombin, factor IXa, factor Xa, and plasmin. Glycosaminoglycans 154-172 plasminogen Homo sapiens 213-220 6448846-6 1980 The second-order rate constants for the neutralization of factor Xa or plasmin by the mucopolysaccharide . Glycosaminoglycans 86-104 plasminogen Homo sapiens 71-78 6448846-17 1980 Thus, our data demonstrate that binding of heparin to antithrombin is required for the mucopolysaccharide-dependent enhancement in the rates of neutralization of thrombin, factor IXa, factor Xa, or plasmin by the protease inhibitor. Glycosaminoglycans 87-105 plasminogen Homo sapiens 198-205 70942-3 1977 Plasmin is localized in the connective tissue and its function is to regulate the turnover of glycosaminoglycans. Glycosaminoglycans 94-112 plasminogen Homo sapiens 0-7 24659483-7 2014 Allosteric inhibitors of plasmin have also been designed including small molecule lysine analogs that bind to plasmin"s kringle domain(s) and sulfated glycosaminoglycan mimetics that bind to plasmin"s catalytic domain. Glycosaminoglycans 151-168 plasminogen Homo sapiens 25-32